• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Can-Fite Biopharma Ltd ADR (NY: CANF )

    2.190 +0.040 (+1.86%)
    Official Closing Price Updated: 6:30 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Can-Fite Biopharma Ltd ADR

    < Previous 1 2 3 4 5 6 7 Next >
    Can-Fite To Reveal Findings In Treatment Of Liver Cancer And Fibrosis With Cannabinoids At CannX
    Dr. Pnina Fishman CEO of Can-Fite BioPharma Ltd. (AMEX:CANF)... 
    Via Benzinga
    Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout From Psoriasis Study
    Citing unanticipated delay in the collection of study data, Can-Fite BioPharma Ltd (NYSE: CANF) said that the topline data from its Phase 3 Comfort study of Piclidenoson... 
    Via Benzinga
    Psoriasis Drug Providers Looking Over Shoulders At Upcoming Competitor?
    Photo by Diana Polekhina on Unsplash 
    Via Benzinga
    Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    CAN-FITE ISSUES LETTER TO SHAREHOLDERS
    Q1 2022: Psoriasis Phase III Data & Commencement of Enrollment in Phase IIb NASH H1 2022: Commencement of Enrollment in Phase III Liver Cancer PETACH TIKVA,... 
    Via Benzinga
    A New Oral Therapy for Psoriasis Could Be Coming Soon
    Photo by Towfiqu barbhuiya on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice... 
    Via Benzinga
    Can Fite's Piclidenoson Destroys Pathological Skin Cells, Lab Study Shows
    Can-Fite BioPharma Ltd (NYSE: CANF) announced preclinical studies with skin cells, modeling psoriasis in humans, showing that Piclidenoson destroys pathological skin... 
    Via Benzinga
    The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
    Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio... 
    Via Benzinga
    PRIOR TO PHASE III PSORIASIS DATA RELEASE CAN FITE REPORTS THAT PICLIDENOSON DESTROYS PATHOLOGICAL SKIN CELLS IN VITRO
    Piclidenoson has been out-licensed for the indication of psoriasis in certain major markets PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American:... 
    Via Benzinga
    Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference
    PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs... 
    Via Benzinga
    Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    Can-Fite Issues Letter to Shareholders
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    FOLLOWING COMPLETE CLEARANCE OF CANCER LESIONS IN ADVANCED LIVER CANCER PATIENT, CAN-FITE IS FILING PATENT APPLICATIONS FOR THE TREATMENT OF VARIOUS ADVANCED SOLID TUMORS
    Namodenoson Headed into Pivotal Phase III Liver Cancer Study PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a... 
    Via Benzinga
    45 Biggest Movers From Yesterday
    Gainers Puxin Limited (NYSE: NEW) shares surged 80% to close at $0.54 on Wednesday after reporting results for the second quarter. United Time Technology Co., Ltd. (NASDAQ: UTME... 
    Via Benzinga
    26 Stocks Moving In Wednesday's Mid-Day Session
    Gainers Puxin Limited (NYSE: NEW) jumped 100.5% to $0.6016 after reporting results for the second quarter. ShiftPixy, Inc. (NASDAQ: PIXY) climbed 38.4% to $1.55 after surging 43... 
    Via Benzinga
    CANF Stock: The Cancer-Fighting News Sending Can-Fite Higher Today
    Can-Fite BioPharma is rising on Wednesday following positive Phase 2 data on its liver cancer treatment. Can it help turn CANF stock around? 
    Via InvestorPlace
    Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    38 Stocks Moving In Tuesday's Mid-Day Session
    Gainers Reliance Global Group, Inc. (NASDAQ: RELI) surged 126% to $6.91 after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) climbed 71.4% to $13.06 after gaining... 
    Via Benzinga
    55 Biggest Movers From Yesterday
    Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) gained 44.8... 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Good morning, trader! We're kicking off the day with a dive into some of the biggest pre-market stock movers for Tuesday! 
    Via InvestorPlace
    26 Stocks Moving in Tuesday's Pre-Market Session
    Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) rose 102% to $5.13 in pre-market trading after the company reported pan-coronavirus monoclonal antibody cocktail that retains... 
    Via Benzinga
    65 Biggest Movers From Yesterday
    Gainers Society Pass Incorporated (NASDAQ: SOPA) shares climbed 240.2% to close at $11.26 on Monday after the company reported addition to the Russell 2000 Index. Bluerock... 
    Via Benzinga
    Mid-Afternoon Market Update: Dow Tumbles 500 Points; Bluerock Residential Growth Shares Spike Higher
    Toward the end of trading Monday, the Dow traded down 1.42% to 34,862.49 while the NASDAQ fell 1.38% to 14,960.51. The S&P also fell, dropping 1.34% to 4,558.87. The U.S. has... 
    Via Benzinga
    Can-Fite Shares Rally As Namodenoson Clears All Cancer Lesions In Liver Cancer Patient
    Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last liver cancer patient treated under an Open-Label Extension program of its concluded Phase 2 study of Namodenoson... 
    Via Benzinga
    Mid-Day Market Update: Crude Oil Drops Over 5%; Society Pass Shares Jump
    Midway through trading Monday, the Dow traded down 1.78% to 34,735.33 while the NASDAQ fell 1.43% to 14,952.69. The S&P also fell, dropping 1.59% to 4,547.26. The U.S. has the... 
    Via Benzinga
    RKT Stock: 15 Things to Know as Rocket Moves Beyond Mortgages With Truebill Deal
    Rocket Companies (RKT) stock is on the move Monday following news of a $1.275 billion acquisition deal with Truebill. 
    Via InvestorPlace
    CANF Stock Alert: The Liver Cancer News Catapulting Can-Fite BioPharma Shares Higher Today
    Can-Fite BioPharma (CANF) stock is rocketing higher on Monday thanks to new data from a Phase II clinical trial for liver cancer. 
    Via InvestorPlace
    38 Stocks Moving In Monday's Mid-Day Session
    Gainers Society Pass Incorporated (NASDAQ: SOPA) shares jumped 120.9% to $7.31 after the company reported addition to the Russell 2000 Index. Can-Fite BioPharma Ltd. (NYSE: CANF... 
    Via Benzinga
    Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study
    From Can-Fite BioPharma Ltd.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.